Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19
Abstract Chloroquine (CQ) and Hydroxychloroquine (HCQ) are antimalarial drugs, with anti-inflammatory properties that justify their use in the treatment of systemic lupus erythematosus and rheumatic diseases. A pandemic caused by the new coronavirus led the entire world’s scientific community to look for drugs already available on the market, capable of exercising beneficial actions in the fight against the disease. Preliminary studies in patients, as well as in vitro studies, suggested possible therapeutic effects associated with the use of HCQ and CQ in the treatment of COVID-19. Despite controversies over the effects of these drugs in combating the “cytokine storm” associated with COVID and the dismal of results in different clinical trials in Brazil, their use has been encouraged and several ongoing investigative studies are underway. In addition to the possible beneficial effects on the prognosis of patients with SARS-CoV-2, such drugs include varied effects on the cardiovascular system, ranging from positive developments related to their vasodilator properties to potential negative effects, such as cardiotoxicity. This work presents the main effects exerted by these drugs on the cardiovascular system, in order to contribute to a scientific discussion about the repurposing of these drugs in the context of COVID-19.
Main Authors: | , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Cardiologia
2021
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-56472021000200211 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S2359-56472021000200211 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S2359-564720210002002112022-02-02Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19Brazão,Stephani CorreiaAutran,Lis JappourLopes,Rosane de OliveiraScaramello,Christianne Brêtas VieiraBrito,Fernanda Carla Ferreira deMotta,Nadia Alice Vieira Cardiovascular System Chloroquine/toxicity Hydroxychloroquine/toxicity Betacoronavirus COVID-19 Azithromycin/ therapeutic use Abstract Chloroquine (CQ) and Hydroxychloroquine (HCQ) are antimalarial drugs, with anti-inflammatory properties that justify their use in the treatment of systemic lupus erythematosus and rheumatic diseases. A pandemic caused by the new coronavirus led the entire world’s scientific community to look for drugs already available on the market, capable of exercising beneficial actions in the fight against the disease. Preliminary studies in patients, as well as in vitro studies, suggested possible therapeutic effects associated with the use of HCQ and CQ in the treatment of COVID-19. Despite controversies over the effects of these drugs in combating the “cytokine storm” associated with COVID and the dismal of results in different clinical trials in Brazil, their use has been encouraged and several ongoing investigative studies are underway. In addition to the possible beneficial effects on the prognosis of patients with SARS-CoV-2, such drugs include varied effects on the cardiovascular system, ranging from positive developments related to their vasodilator properties to potential negative effects, such as cardiotoxicity. This work presents the main effects exerted by these drugs on the cardiovascular system, in order to contribute to a scientific discussion about the repurposing of these drugs in the context of COVID-19.info:eu-repo/semantics/openAccessSociedade Brasileira de CardiologiaInternational Journal of Cardiovascular Sciences v.34 n.2 20212021-04-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-56472021000200211en10.36660/ijcs.20200162 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Brazão,Stephani Correia Autran,Lis Jappour Lopes,Rosane de Oliveira Scaramello,Christianne Brêtas Vieira Brito,Fernanda Carla Ferreira de Motta,Nadia Alice Vieira |
spellingShingle |
Brazão,Stephani Correia Autran,Lis Jappour Lopes,Rosane de Oliveira Scaramello,Christianne Brêtas Vieira Brito,Fernanda Carla Ferreira de Motta,Nadia Alice Vieira Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19 |
author_facet |
Brazão,Stephani Correia Autran,Lis Jappour Lopes,Rosane de Oliveira Scaramello,Christianne Brêtas Vieira Brito,Fernanda Carla Ferreira de Motta,Nadia Alice Vieira |
author_sort |
Brazão,Stephani Correia |
title |
Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19 |
title_short |
Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19 |
title_full |
Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19 |
title_fullStr |
Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19 |
title_full_unstemmed |
Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19 |
title_sort |
effects of chloroquine and hydroxychloroquine on the cardiovascular system - limitations for use in the treatment of covid-19 |
description |
Abstract Chloroquine (CQ) and Hydroxychloroquine (HCQ) are antimalarial drugs, with anti-inflammatory properties that justify their use in the treatment of systemic lupus erythematosus and rheumatic diseases. A pandemic caused by the new coronavirus led the entire world’s scientific community to look for drugs already available on the market, capable of exercising beneficial actions in the fight against the disease. Preliminary studies in patients, as well as in vitro studies, suggested possible therapeutic effects associated with the use of HCQ and CQ in the treatment of COVID-19. Despite controversies over the effects of these drugs in combating the “cytokine storm” associated with COVID and the dismal of results in different clinical trials in Brazil, their use has been encouraged and several ongoing investigative studies are underway. In addition to the possible beneficial effects on the prognosis of patients with SARS-CoV-2, such drugs include varied effects on the cardiovascular system, ranging from positive developments related to their vasodilator properties to potential negative effects, such as cardiotoxicity. This work presents the main effects exerted by these drugs on the cardiovascular system, in order to contribute to a scientific discussion about the repurposing of these drugs in the context of COVID-19. |
publisher |
Sociedade Brasileira de Cardiologia |
publishDate |
2021 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-56472021000200211 |
work_keys_str_mv |
AT brazaostephanicorreia effectsofchloroquineandhydroxychloroquineonthecardiovascularsystemlimitationsforuseinthetreatmentofcovid19 AT autranlisjappour effectsofchloroquineandhydroxychloroquineonthecardiovascularsystemlimitationsforuseinthetreatmentofcovid19 AT lopesrosanedeoliveira effectsofchloroquineandhydroxychloroquineonthecardiovascularsystemlimitationsforuseinthetreatmentofcovid19 AT scaramellochristiannebretasvieira effectsofchloroquineandhydroxychloroquineonthecardiovascularsystemlimitationsforuseinthetreatmentofcovid19 AT britofernandacarlaferreirade effectsofchloroquineandhydroxychloroquineonthecardiovascularsystemlimitationsforuseinthetreatmentofcovid19 AT mottanadiaalicevieira effectsofchloroquineandhydroxychloroquineonthecardiovascularsystemlimitationsforuseinthetreatmentofcovid19 |
_version_ |
1756441640093876224 |